Search hospitals > Massachusetts > Boston
Dana Farber Cancer Institute
Claim this profileBoston, Massachusetts 02215
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Tumors
Conducts research for Leukemia
Conducts research for Lymphoma
3428 reported clinical trials
267 medical researchers
Summary
Dana Farber Cancer Institute is a medical facility located in Boston, Massachusetts. This center is recognized for care of Cancer, Breast Cancer, Tumors, Leukemia, Lymphoma and other specialties. Dana Farber Cancer Institute is involved with conducting 3,428 clinical trials across 1,342 conditions. There are 267 research doctors associated with this hospital, such as Susan Chi, MD, Haeseong Park, MD, Geoffrey I. Shapiro, and Ryan Sullivan, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
Stage III
HER2 negative
Top PIs
Susan Chi, MDDana-Farber Cancer Institute4 years of reported clinical research
Expert in Brain Tumor
Expert in Diffuse Intrinsic Pontine Glioma
28 reported clinical trials
60 drugs studied
Haeseong Park, MDWashington University School of Medicine5 years of reported clinical research
Studies Adenocarcinoma
Studies Solid Tumors
27 reported clinical trials
55 drugs studied
Geoffrey I. ShapiroDana-Farber Cancer Institute7 years of reported clinical research
Expert in Solid Tumors
Expert in Tumors
26 reported clinical trials
57 drugs studied
Ryan Sullivan, MDMassachusetts General Hospital2 years of reported clinical research
Expert in Melanoma
Studies Solid Tumors
20 reported clinical trials
33 drugs studied
Clinical Trials running at Dana Farber Cancer Institute
Breast Cancer
Multiple Myeloma
Non-Small Cell Lung Cancer
Brain Tumor
Plasma Cell Neoplasms
Lymphoma
Melanoma
Lung Cancer
B-Cell Lymphoma
Neurofibromatosis
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Recruiting4 awards Phase 3
Avelumab + Palbociclib/Hydroxychloroquine
for Breast Cancer
This study is evaluating whether a drug called hydroxychloroquine can be used to treat early stage breast cancer.
Recruiting3 awards Phase 212 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Dana Farber Cancer Institute?
Dana Farber Cancer Institute is a medical facility located in Boston, Massachusetts. This center is recognized for care of Cancer, Breast Cancer, Tumors, Leukemia, Lymphoma and other specialties. Dana Farber Cancer Institute is involved with conducting 3,428 clinical trials across 1,342 conditions. There are 267 research doctors associated with this hospital, such as Susan Chi, MD, Haeseong Park, MD, Geoffrey I. Shapiro, and Ryan Sullivan, MD.
Where is Dana Farber Cancer Institute located?
The Dana Farber Cancer Institute is situated at 450 Brookline Ave, Boston, MA 02215, within the Longwood Medical Area. For access from the north, utilize I-93, the Tobin Bridge (Route 1), and Route 28, directing towards Storrow Drive, then proceed for 1.5 miles. Follow the exit for Kenmore Square/Fenway, Route 1S, stay in the far left lane, and continue onto Boylston Street (outbound), then bear slight left onto Brookline Avenue, and turn left onto Jimmy Fund Way to find the parking garage entrance on the right.
Who should I call to ask about financial aid or insurance network?
**Dana Farber Cancer Institute Contact Information:**
- **Patient Billing Solutions Team:** For general financial inquiries and assistance with the Patient Financial Assistance program, call 617-632-3795.
- **Shapiro Center for Patients and Families:** For insurance and financial information questions, contact 617-632-3750.
- **International Office:** Specialized support for international patients is available.
- **Language Assistance:** Spanish-speaking patients can call 617-632-3673. For all other languages, please call 617-632-6366.
**Address:** 450 Brookline Ave., Boston, MA 02215-5450.
What insurance does Dana Farber Cancer Institute accept?
The Dana Farber Cancer Institute accepts a wide range of insurance plans, such as Aetna, Allways Health Partners, AmeriHealth, Anthem, Cigna, Humana, Oscar, and UnitedHealthcare. It is now an in-network provider for the Boston Medical Center HealthNet Plan (BMCHP), catering to Massachusetts residents, including MassHealth members from marginalized communities, individuals with disabilities, and seniors. The hospital offers specialized services for international patients and financial counseling for uninsured or low-income individuals to explore coverage options.
What awards or recognition has Dana Farber Cancer Institute received?
The Dana-Farber Cancer Institute in Boston, Massachusetts, is renowned for its exceptional research and care in the field of cancer. It has been recognized as one of the most noteworthy companies and non-profits led by women in Massachusetts. Furthermore, 24 of its researchers have been acknowledged as Highly Cited Researchers, underscoring their significant global impact on cancer research.